81.8% of patients with bothersome tinnitus treated with Lenire at New York Hearing Doctors reported significant improvement in a real-world clinical setting.1,2 Patients with bothersome tinnitus reported a 23.8 point mean reduction in tinnitus as measured by the Tinnitus Handicap Inventory, which is greater than three times the threshold for clinical significance.1,2 The majority of patients with bothersome tinnitus reported they were no longer severely impacted by their tinnitus following 12-

UPPSALA, Sweden, Feb. 17, 2026 /PRNewswire/ -- Beactica Therapeutics AB, a Swedish precision medicine company, today announced that it, together with leading glioblastoma researchers at KU Leuven, has been awarded a EUR 2.5 million grant by the European Innovation Council (EIC) to advance a precision immune therapy for glioblastoma, the most common and aggressive brain tumour which currently lacks effective treatment. In the project GLIOBREAK, Beactica and KU Leuven are joining forces to advance

Newron Pharmaceuticals S.p.A. (“Newron”, or the “Company”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it has entered into an agreement for the subscription of newly issued shares for proceeds of up to EUR 38 million with a group of existing and new shareholders from Europe and Asia, strengthening the Company’s financial position as it advances the

Immunic has announced an oversubscribed private placement of up to $400m, strengthening its move from an R&D-focused organisation into a commercial-stage entity. The placement was led by existing investor BVF Partners and joined by entities such as Avidity Partners, OrbiMed, Trails Edge Capital Partners, TCGX, Vivo Capital and other institutional investors. The company will also use the proceeds for completing its ongoing Phase III ENSURE studies of vidofludimus calcium in relapsing multiple s

Clinical Advisory Board formed to support progression of HRN001 into first-in-human studies in 2027 Dr Andy Billinton, CSO will present preclinical data at the upcoming CHDI Foundation Huntington’s Disease Therapeutics Conference 16 February 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces the nomination of HRN001 as its lead drug candidate for Huntington's disease

CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients with advanced solid tumors. This marks a significant milestone in the global development of this innovative immunotherapy. The ongoing global multicenter Phase II trial is currently enrolling patients in Australia and China. The study design includes 15 cohorts evaluating both monotherapy and comb

Gilead is buying the global rights to an oral cancer drug from Genhouse Bio, a China-based biotech that filed for an IPO on the Hong Kong Stock Exchange last month. The California drugmaker is dishing out $80 million upfront for GH31, a MAT2A-targeted synthetic lethality drug for select solid tumors. MAT2A plays a role in metabolic regulation and can be overexpressed in cancer cells. Genhouse could get up to $1.45 billion in biobucks, the company announced Friday on WeChat. A Gilead spokespers

Feb. 13, 2026-- A newly published scientific paper titled " Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration" (Csonka, G.I.; Papp, A.; Somlyai, I.; Somlyai, G. Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration. Int. J. Mol. Sci. 2025, 26, 10969. https://doi.org/10.3390/ijms262210969) has validated a groundbreaking mechanism that has been at the core of HYD LLC for Cancer Research and Drug

With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. Late Thursday, PTC revealed that it withdrew its FDA application for Translarna in nonsense mutation DMD after receiving feedback on its filing from the regulator. "FDA shared that based on its review to date, the data in the [New Drug Application] submission are unlikely to meet the Agency's threshold of substantial evidence of effe

Novel intravenous anti-inflammatory candidate advances to Phase I evaluation to assess safety, tolerability, and pharmacokinetics. February 11, 2026-- Isosceles Pharmaceuticals today announced that its patented investigational candidate, IPI201, has been accepted to proceed into a Phase I first-in-human clinical trial, marking a milestone in the company’s development pipeline. The study is expected to initiate first patient, first dose in April, beginning with dosing in healthy volunteers. IPI